FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number:	3235-028								
Estimated average b	ourden								

0.5

hours per response:

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security		3A. Deeme Execution if any (Month/Day	d 4 Date, 1 (y/Year) 8	Juts,  I.  Irransa Code (13)	action	5. N of Deri Sec Acq (A) o Disp	umber vative urities uired	6. Date	ate Exe iration nth/Day	ercisa Date y/Yea	ble and	OI No		Amount s Security 4)  Amount or	8. Price of Derivative Security (Instr. 5)		e s ally g i	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership t (Instr. 4)		
Common Stock Table II - Deri																	17,022		I	9,522 shares 401(k); 207,500 shares in crust <sup>(2)</sup>		
Common	Stock			09/02	2/200	)3				S <sup>(1)</sup>		20,000		D	\$12.5	2 8	50,977	D				
Common Stock					09/02/2003						V	20,000	-	(A) or (D)	Price \$7.8	(Instr.	3 and 4)		D	$\overline{}$		
1. Title of Security (Instr. 3)			2. Transaction Date (Month/Day/Year)		n (ear)	2A. Deemed Execution Date,		ar) 8	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4		(A) or 3, 4 and	or 5. Amour Securitie Beneficia Owned F		Form (D) o	: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)				
(City)	(.	State) 	(Zip) able I - No	n-Deriv	 /ativ	re Se	curi	ties A	caui	ired.	Disi	oosed of	f. or	r Bene	 eficial	v Owne	d					
(Street) CAMBR		ИΑ	02139			Line)  X Form filed by On  Form filed by Mo  Person											filed by Mo					
130 WAV	ERLY ST	REET	4. 1	If Ame	endme	nt, Date	of Or	iginal F	iled	(Month/Day	//Yea	ar)		6. Individual or Joint/Group Filing (Check Applicable								
(Last) (First) (Middle) C/O VERTEX PHARMACEUTICALS INCORPORATED						Date 0		iest Tran	sactio	on (Mo	nth/D	ay/Year)		20.0	Chairman & CEO							
						<u>IA</u> [	VRT	<b>x</b> ]					- 1	X Direct X Offict below	er (give title		10% Ov Other (s below)					
1. Name and Address of Reporting Person*  BOGER JOSHUA S																	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					

## Explanation of Responses:

- 1. Transaction made pursuant to Dr. Boger's company approved trading plan established under Rule 10b5-1.
- 2. Shares held in trust for Dr. Boger's children. Dr. Boger disclaims beneficial ownership of such shares.
- 3. Right to buy under 1991 Stock and Option Plan, vesting in 20 equal quarterly installments from 12/01/1993.

## Remarks:

Valerie L. Andrews, Attorney-

09/03/2003

<u>In-Fact</u>

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.